Proteios Technology, Inc.’s Post

Proteios has been selected as a member of CASA-Bio (Catalyzing Across Sectors to Advance the Bioeconomy) to advance biotechnology and biomanufacturing through foundational and use-inspired research and development.  CASA-Bio was created on September 2022 by Executive Order (EO) on “Advancing Biotechnology and Biomanufacturing Innovation for a Sustainable, Safe, and Secure American Bioeconomy.”  Proteios is participating under the “Human Health” EO Bioeconomy theme with our novel multidimensional cell isolation technology to provide clinicians with unprecedented access to immune cell subpopulations and precise control of cell therapy compositions.  Cell therapies, especially in cancer treatment like CAR-T cell therapies, present a vast untapped potential but face significant challenges in basic science, cell sourcing, manufacturing, and in vivo performance control.  Proteios looks forward to addressing these challenges to improve the range of conditions for which cell therapies can be routinely applied.

To view or add a comment, sign in

Explore topics